Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application

Table 2

Clinical trials of single-agent therapy with bevacizumab in ovarian cancer.

Trial number	Phase	Stage of the disease	Number of patients	CR	PR	MPFS (m)	MOS (m)
Completed
NCT00022659 (GOG170D) [37]	II	Persistent or recurrent EOC or PPC	62	3%	18%	4.7	17
NCT00097019 (AVF2949g) [38]	II	Recurrent EOC or PSC	44	0	15.9%	4.4	10.7
Ongoing
NCT00866723(08-323)*	II	Relapse after bevacizumab maintenance therapy	32	N/A	N/A	N/A	N/A

EOC: epithelial ovarian cancer, PPC: primary peritoneal cancer, PSC: peritoneal serous carcinoma, CR: complete response, PR: partial response, MPFS: median progression-free survival, MOS: median overall survival, m: months, N/A: nonaccessible.
*Accessed from http://www.clinicaltrials.gov/ on April 18, 2011.